Streptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

DB16710ApprovedInvestigationalVaccines

Streptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 22F individually conjugated to... It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection.

First approval
Canada, 2005 · United States, 2021 · European Union, 2022
Also known as
Streptococcus pneumoniae serotype 22F capsular antigen diphtheria CRM197 protein conjugate vaccine
Brand names
  • Apexxnar
  • Capvaxive
  • Prevnar 20
  • Vaxneuvance

Resolves to

Compound
UNIIU1E9VSB2K2
Clinical / RWD
RxNorm2566297

What you can answer from here — as of August 01, 2026

46Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
14Marketed productsAcross 3 countries and 7 labellers
Sign in

Which other approved drugs treat the same conditions as Streptococcus pneumoniae type 22F capsular polysaccharide diphtheria CRM197 protein conjugate antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In